Abstract Number: 1345 • 2012 ACR/ARHP Annual Meeting
Validation of the Health Assessment Questionnaire for Spondyloarthritis in Patients with Non-Radiographic Axial Spondyloarthritis
Background/Purpose: To evaluate the psychometric properties of the Health Assessment Questionnaire for Spondyloarthritis (HAQ-S) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Methods: Data from 185…Abstract Number: 1346 • 2012 ACR/ARHP Annual Meeting
Comparison of Three Screening Tools in Psoriatic Arthritis: The Contest Study
Background/Purpose: The majority of patients with PsA have psoriasis prior to arthritis and there is evidence that a significant proportion of patients in dermatology clinics…Abstract Number: 1347 • 2012 ACR/ARHP Annual Meeting
Anti-TNFá Discontinuation in Psoriatic Arthritis: Is It Possible After Achieving Minimal Disease Activity?
Background/Purpose: Remission in Psoriatic Arthritis, defined as a period of at least 3 consecutive visits with no actively inflamed joints, occurs in about 17 percent…Abstract Number: 1348 • 2012 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic Arthritis
Background/Purpose: Spondylitis in Psoriatic Arthritis (PsA) sometimes resembles DISH because of the presence of juxta-vertebral calcification that resemble syndesmophytes. Distinguishing spondylitis from DISH has therapeutic…Abstract Number: 1349 • 2012 ACR/ARHP Annual Meeting
Trends in Incidence and Clinical Features of Ankylosing Spondylitis in Olmsted County (1980-2009): A Population Based Study
Background/Purpose: To determine trends in the incidence and clinical presentation of ankylosing spondylitis (AS) among residents of a geographically defined area first diagnosed 1980-2009 and…Abstract Number: 1350 • 2012 ACR/ARHP Annual Meeting
Inflammatory Biomarkers in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that may progress rapidly and result in joint damage and disability. The aim of this study was…Abstract Number: 1351 • 2012 ACR/ARHP Annual Meeting
Ultrasonographic Entheseal Abnormalities Among Patients with Psoriatic Arthritis, Psoriasis Alone and Healthy Individuals and Their Correlation with Disease-Related Variables
Background/Purpose: Enthesitis is an important manifestation of psoriatic arthritis (PsA). We aimed to compare the frequency of ultrasonographic (US) entheseal abnormalities between patients with PsA,…Abstract Number: 1352 • 2012 ACR/ARHP Annual Meeting
Adalimumab Significantly Reduces Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis
Background/Purpose : A high percentage (30-40%) of patients with Ankylosing Spondylitis (AS) suffer from acute anterior uveitis (AAU) attacks. Local treatment with corticosteroids is a…Abstract Number: 1353 • 2012 ACR/ARHP Annual Meeting
Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Nonradiographic Axial Spa: Wk-52 Results From Ability-1
Background/Purpose: To evaluate long-term effects of adalimumab (ADA) treatment on patient reported outcomes (PROs) in nonradiographic axial spondyloarthritis (nr-axSpA). Methods: Ability-1 is an ongoing Phase…Abstract Number: 1354 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Psoriatic Arthritis Based On Rheumatologists’ Clinical Assessment Before and After Laboratory and Radiographic Tests in Psoriasis Patients in European/North American Dermatology Clinics
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease with a heterogeneous presentation that is associated with impaired quality of life, joint damage, and limited…Abstract Number: 1355 • 2012 ACR/ARHP Annual Meeting
Hand Bone Loss Is Arrested in Early Psoriatic Arthritis but Not in Rheumatoid Arthritis Following Anti-Rheumatic Treatment Assessed by Digital X-Ray Radiogrammetry
Background/Purpose: Periarticular bone loss is an early feature of both psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Digital X-ray radiogrammetry (DXR) is a sensitive method…Abstract Number: 1316 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Background/Purpose: Certolizumab pegol (CZP) has been shown to be efficacious and have an acceptable safety profile when administered every 4 weeks (Q4W) as monotherapy (FAST4WARD,…Abstract Number: 1317 • 2012 ACR/ARHP Annual Meeting
One-Year Results From the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in Rheumatoid Arthritis
Background/Purpose: Combination therapy with a biologic and methotrexate (MTX) usually yields better outcomes than biologic monotherapy in rheumatoid arthritis (RA).1,2,3 However, patients may be intolerant…Abstract Number: 1318 • 2012 ACR/ARHP Annual Meeting
Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Background/Purpose: Certolizumab pegol (CZP) monotherapy administered every 4 weeks (Q4W) for rheumatoid arthritis (RA) has been shown to be associated with rapid and sustainable improvements…Abstract Number: 1319 • 2012 ACR/ARHP Annual Meeting
Certolizumab Pegol Plus Methotrexate Is Similarly Effective in Active Rheumatoid Arthritis Secondary Non-Responders to Anti-TNF Inhibitors: Post-Hoc Analysis of a Phase Iiib Trial
Background/Purpose: Certolizumab pegol (CZP) has demonstrated efficacy in patients (pts) with prior TNF inhibitor exposure.1 In the Doseflex trial two maintenance dosing regimens of CZP…